Combination therapy explained

Combination therapy or polytherapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression). 'Pharmaceutical' combination therapy may be achieved by prescribing/administering separate drugs, or, where available, dosage forms that contain more than one active ingredient (such as fixed-dose combinations).

Polypharmacy is a related term, referring to the use of multiple medications (without regard to whether they are for the same or separate conditions/diseases). Sometimes "polymedicine" is used to refer to pharmaceutical combination therapy. Most of these kinds of terms lack a universally consistent definition, so caution and clarification are often advisable.

Uses

Conditions treated with combination therapy include tuberculosis, leprosy, cancer, malaria, and HIV/AIDS. One major benefit of combination therapies is that they reduce development of drug resistance since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. Artemisinin-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment.

Combination therapy may seem costlier than monotherapy in the short term, but when it is used appropriately, it causes significant savings: lower treatment failure rate, lower case-fatality ratios, fewer side-effects than monotherapy, slower development of resistance, and thus less money needed for the development of new drugs.[1]

In oncology

Combination therapy has gained momentum in oncology in recent years, with various studies demonstrating higher response rates with combinations of drugs compared to monotherapies,[2] [3] and the FDA recently approving therapeutic combination regimens that demonstrated superior safety and efficacy to monotherapies.[4] In a recent study about solid cancers, Martin Nowak, Bert Vogelstein, and colleagues showed that in most clinical cases, combination therapies are needed to avoid the evolution of resistance to targeted drugs. Furthermore, they find that the simultaneous administration of multiple targeted drugs minimizes the chance of relapse when no single mutation confers cross-resistance to both drugs.

Various systems biology methods must be used to discover combination therapies to overcome drug resistance in select cancer types.[5] [6] Recent precision medicine approaches have focused on targeting multiple biomarkers found in individual tumors by using combinations of drugs.[7] [8] However, with 300 FDA-approved cancer drugs on the market, there almost 45,000 possible two-drug combinations and almost 4.5 million three-drug combinations for to choose from.[9] That level of complexity is one of the primary impediments to the growth of combination therapy in oncology.

The National Cancer Institute has recently highlighted combination therapy as a top research priority in oncology.[10]

Bacterial infections

Combination therapy with two or more antibiotics are often used in an effort to treat multi-drug resistant Gram-negative bacteria.[11]

Contrast to monotherapy

Monotherapy, or the use of a single therapy, can be applied to any therapeutic approach, but it is most commonly used to describe the use of a single medication. Normally, monotherapy is selected because a single medication is adequate to treat the medical condition. However, monotherapies may also be used because of unwanted side effects or dangerous drug interactions.[12]

See also

External links

Notes and References

  1. Bozic. Reiter. Allen. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. June 25, 2013. 2:e00747. e00747. 10.7554/eLife.00747. 23805382. 3691570. etal . free .
  2. Janku. Filip. Hong. David S.. Fu. Siqing. Piha-Paul. Sarina A.. Naing. Aung. Falchook. Gerald S.. Tsimberidou. Apostolia M.. Stepanek. Vanda M.. Moulder. Stacy L.. 2014-01-30. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Reports. 6. 2. 377–387. 10.1016/j.celrep.2013.12.035. 2211-1247. 4409143. 24440717.
  3. Musgrove. Elizabeth A.. Caldon. C. Elizabeth. Barraclough. Jane. Stone. Andrew. Sutherland. Robert L.. 2011-07-07. Cyclin D as a therapeutic target in cancer. Nature Reviews. Cancer. 11. 8. 558–572. 10.1038/nrc3090. 1474-1768. 21734724. 29093377.
  4. Web site: Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer Novartis US. www.pharma.us.novartis.com. en. 2017-10-03. https://web.archive.org/web/20171004085534/https://www.pharma.us.novartis.com/news/media-releases/novartis-receives-fda-approval-first-its-kind-kisqalir-femarar-co-pack-initial. 2017-10-04. dead.
  5. Korkut. A. Wang. W. Demir. E. Aksoy. BA. Jing. X. Molinelli. EJ. Babur. Ö. Bemis. DL. Onur Sumer. S. Solit. DB. Pratilas. CA. Sander. C. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.. eLife. 18 August 2015. 4. 26284497. 10.7554/elife.04640. 4539601. free.
  6. Lee. MJ. Ye. AS. Gardino. AK. Heijink. AM. Sorger. PK. MacBeath. G. Yaffe. MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.. Cell. 11 May 2012. 149. 4. 780–94. 22579283. 10.1016/j.cell.2012.03.031. 3501264.
  7. Web site: Drug Combinations to Overcome Treatment Resistance. National Cancer Institute. en. 2017-10-03. 2016-12-21.
  8. Li . Xubin . Dowling . Elisabeth K. . Yan . Gonghong . Dereli . Zeynep . Bozorgui . Behnaz . Imanirad . Parisa . Elnaggar . Jacob H. . Luna . Augustin . Menter . David G. . Pilié . Patrick G. . Yap . Timothy A. . 2022-05-02 . Precision Combination Therapies Based on Recurrent Oncogenic Coalterations . Cancer Discovery . 12 . 6 . en . OF1–OF18 . 10.1158/2159-8290.CD-21-0832 . 35412613 . 9524464 . 2159-8274.
  9. News: By the Numbers: Combination Therapy in Oncology CureMatch. Culjat. M. 2017-05-11. CureMatch Blog. 2017-10-03. en-US.
  10. Web site: Combination Therapies for Cancer - Annual Plan. National Cancer Institute. https://web.archive.org/web/20171005013739/https://www.cancer.gov/about-nci/budget/plan/treating/combining-therapies. en. 2017-10-03. 2017-10-05.
  11. Tamma. P. D.. Cosgrove. S. E.. Maragakis. L. L.. 2012-07-01. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. Clinical Microbiology Reviews. en. 25. 3. 450–470. 10.1128/CMR.05041-11. 0893-8512. 3416487. 22763634.
  12. Web site: Glossary . 2008-04-02 . Monotherapy: The treatment of epilepsy with a single medication rather than a combination. Monotherapy has advantages over combining medications in many patients, including absence of drug-drug interactions, fewer side effects, simpler dosing, and lower cost. However, not all patients can be controlled with monotherapy. . https://web.archive.org/web/20080907194848/http://www.epilepsy.uhhs.com/glossary.htm . 2008-09-07 . dead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Combination therapy".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.